R
  • 773.714.0705
  • Home
  • About Us
  • Specialty
    • Allergy/Immunology (9)
    • Cardiology (10)
    • Critical/Intensive Care (5)
    • Dentistry (2)
    • Dermatology (6)
    • Emergency Medicine (16)
    • Endocrinology (7)
    • ENT/Otolaryngology (1)
    • Family/General Practice (45)
    • Gastroenterology (11)
    • Geriatrics (18)
    • Hematology (14)
    • Hepatology (1)
    • Hospital Medicine (23)
    • Infectious Disease (7)
    • Internal Medicine (47)
    • Nephrology (3)
    • Neurology (14)
    • Nutrition (3)
    • Obesity Medicine (1)
    • Obstetrics and Gynecology (12)
    • Oncology (20)
    • Ophthalmology (2)
    • Optometry (1)
    • Orthopedics (4)
    • Pain Management (1)
    • Pathology (14)
    • Pediatrics (15)
    • Pharmacy (30)
    • Physiatrists/Rehab Medicine (5)
    • Psychiatry (6)
    • Pulmonology (15)
    • Radiology (9)
    • Respiratory Therapy (5)
    • Rheumatology (4)
    • Sleep Medicine (2)
    • Surgery (16)
    • Urgent Care (2)
    • Urology (3)
  • Activities
    • Live
    • Online
  • Outcomes & Toolkits
New User? Login

Practical Strategies for Multidisciplinary Recognition and Management of Adverse Events Associated with Bispecific Antibodies for R/R Multiple Myeloma

Practical Strategies for Multidisciplinary Recognition and Management of Adverse Events Associated With Bispecific Antibodies for R/R Multiple Myeloma
Practical Strategies for Multidisciplinary Recognition and Management of Adverse Events Associated With Bispecific Antibodies for R/R Multiple Myeloma
Interactive Practice Guide

The expanding armamentarium of therapies for relapsed/refractory (R/R) multiple myeloma (MM) shifts the therapy selection process from a simple algorithmic approach to an individualized approach that requires consideration of the nature of relapse, previous therapies, treatment-related toxicities, as well as patient comorbidities and preferences. But many clinicians lack knowledge around the MOAs of novel therapies, including bispecific antibodies which have a unique set of toxicities. Ensuring optimal treatment outcomes for patients with R/R MM requires a well-coordinated multidisciplinary/multispecialty team to have a clear understanding of these adverse reactions and strategies to monitor and mitigate treatment-related adverse events associated with bispecific antibodies. This learning hub provides multidisciplinary clinicians with the education and resources needed to effectively translate the latest evidence into routine clinical practice.

Faculty: Beth Faiman PhD; Rebecca LaRue, PharmD; Hans Lee, MD

Release Date: February 03, 2025

Expiration Date: February 03, 2026

CME/CE is no longer available for this activity

ACHL - Academy for Continued Healthcare Learning

308 S. Jefferson St.,
Suite 312,
Chicago, IL 60661

  • Phone: 773.714.0705
  • Fax: 773.714.0707
  • Home
  • Specialty
  • Sitemap
  • Privacy Policy
  • Contact Us
  • Follow us on Twitter
  • Like us on Facebook
  • Follow us on LinkedIn

Copyright © 2026 Academy for Continued Healthcare Learning. All Rights Reserved.